Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Operating margin
Kiniksa Pharmaceuticals International (KNSA) operating margin by quarter
Kiniksa Pharmaceuticals International's operating margin was 19.0% in Q3 2026 (third quarter 2026), +7.8 pts from Q2 2026. Over the last 7 quarters it ranged from 9.6% (Q1 2025) to 19.0% (Q3 2026).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 19.0% | +7.8 pts | +5.7 pts |
| Q2 2026 | 11.2% | -2.5 pts | -1.7 pts |
| Q1 2026 | 13.7% | +3.9 pts | +4.0 pts |
| Q4 2025 | 9.8% | -3.5 pts | — |
| Q3 2025 | 13.3% | +0.4 pts | — |
| Q2 2025 | 12.9% | +3.2 pts | — |
| Q1 2025 | 9.6% | — | — |
Q3 2026 at a glance
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Kiniksa Pharmaceuticals International's operating margin?
Kiniksa Pharmaceuticals International's operating margin was 19.0% in Q3 2026 (third quarter 2026), +7.8 pts from Q2 2026.
How has Kiniksa Pharmaceuticals International's operating margin changed?
Over the last 7 quarters it ranged from 9.6% (Q1 2025) to 19.0% (Q3 2026).
Q3 2026 results → · How Kiniksa Pharmaceuticals International makes money →